Search This Blog

Wednesday, June 17, 2015

Eli Lilly and Company Enters Into Strategic Partnership with Sarah Cannon Research Institute to Develop Investigational Oncology Therapy (NYSE:LLY)

INDIANAPOLIS and NASHVILLE, Tenn., June 17, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sarah Cannon Research Institute (SCRI) today announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.



Eli Lilly and Company Enters Into Strategic Partnership with Sarah Cannon Research Institute to Develop Investigational Oncology Therapy (NYSE:LLY)
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)